H 100 - Humanetics Corporation
Latest Information Update: 19 Mar 2014
Price :
$50 *
At a glance
- Originator Humanetics Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 19 Mar 2014 No development reported - Phase-I for Bacterial infections in USA (PO)
- 19 Jan 2006 Phase-I clinical trials in Bacterial infections in USA (PO)